AstraZeneca UK Ltd.
Division of AstraZeneca PLC
Latest From AstraZeneca UK Ltd.
AstraZeneca is hoping that when it files for approval in the EU of its PD-L1 blocker, Imfinzi (durvalumab), for Stage III lung cancer, it will be given accelerated assessment on the back of the PACIFIC data.
As predicted by Scrip last July, WuXi AppTec has moved one step closer to spinning out its biologics unit through an IPO on the Hong Kong equity market, while its main business unit is also proceeding with plans for a China domestic relisting.
Lung cancer drug, recently approved in the US as Tagrisso, is fourth product made available early to UK patients as it awaits EU marketing approval.
Sponsors and regulators continue to develop methodologies with a range of complexity for presenting, communicating and discussing a drug’s risks and benefits.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.